[The role of danazol in the treatment of benign mastopathies]

C. De Noblens
Revue francaise de gynecologie et d'obstetrique · 1992 · vol. 87(11) , pp. 564–6 · PMID:1480927 · W2402884799
Review OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-08-28 ⓘ

This paper defines benign mastopathy as a diverse group of non-cancerous mammary gland lesions, including dystrophic, tumoral, and inflammatory forms, while noting that borderline lesions serve as risk factors for breast cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Benign mastopathy is defined as a non-cancerous lesion of the mammary gland, which may be dystrophic, tumoral or inflammatory. This makes clear the highly diverse nature and wide diversity of clinical forms. Borderline lesions constitute a risk factor for breast cancer.

My notes (saved in your browser only)

MeSH descriptors

Breast Diseases Danazol Adult Breast Diseases Breast Diseases Breast Diseases Clinical Trials as Topic Danazol Danazol Danazol Female Humans

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T11:27:34.212363+00:00
pubmed
last seen: 2026-10-08T21:02:19.201584+00:00
License: CC0 · commercial use OK